Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Christian will be presenting at next-gen-conjugates
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(40)
•••
Comment by Lee430on Nov 01, 2023 2:06pm
78 Views
Post# 35711734

RE:Christian will be presenting at next-gen-conjugates

RE:Christian will be presenting at next-gen-conjugates Question: Is the last presentation of the day when attendees eyes are kind of glassed over from information overload and probably just looking get out of there to grab some liquid dinner a not so good slot? oh and just a 15 minute slot seems pretty short with no time for Q&A or is that for after the presentation?

scarlet1967 wrote:

4:45 pm Targeting Sortilin (SORT1) to Unlock the Potential of Peptide Drug Conjugates (PDCs) in Oncology: Rapid Internalization and Improved Tumor Penetration Within Minutes

 

Synopsis

  • Understand the rationale for targeting the SORT1 receptor in cancer
  • Discuss the preclinical as well as the emerging clinical data of sudocetaxel zendusortide (TH1902), the lead PDC from Theratechnologies’ SORT1+ Technology™ platform
  • Discuss the unique multimodal MOA of this PDC
  • Explore the potential of SORT1+ Technology™ for future developments, such as novel PDC’s and combinations

https://next-gen-conjugates.com/whats-on/day-two/



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities